Tension-type headache and effective pain relief: results of the prospective multicenter RAPID clinical trial

Pharmacological treatment of tension-type headache (TTH) attacks involves the selection of the most effective and safe analgesic. However, the choice of medication is limited by the insufficient number of evidence-based studies for this type of headache (HA).

Objective: to evaluate the efficacy, safety, and tolerability of fast-release lornoxicam (Xefocam rapid) compared to standard lornoxicam (Xefocam), naproxen, and ibuprofen in relieving headache episodes in patients with frequent episodic TTH in routine clinical practice.

Material and methods. The multicenter, observational (non-interventional), prospective RAPID study was conducted in 10 clinical centers across the Russian Federation and included 400 adult patients (74.5% women, 25.5% men) aged 18 to 76 years (mean age: 39.83±12.58 years) with frequent episodic TTH who were prescribed one of the following NSAIDs in routine practice: Xefocam, Xefocam rapid, ibuprofen, or naproxen. The following outcomes were assessed: the number of completely relieved TTH episodes, changes from baseline in the mean number of headache days, mean number of TTH episodes per month, mean duration of TTH episodes, and mean pain intensity on a numerical rating scale, time from drug intake to partial and complete relief of a TTH episode, mean number of days with intake of the drugs in question, number of patients using NSAIDs ≥15 days per month, number of patients taking additional medications for TTH relief, patient satisfaction with the prescribed treatment, number of patients who discontinued treatment, and the frequency of adverse events during therapy.

Results. The study demonstrated overall high efficacy of Xefocam and Xefocam rapid in relieving TTH attacks. At the same time, the data obtained allow the identification of some priority effects of investigated drugs. Thus, Xefocam and Xefocam rapid showed the highest efficacy in achieving complete headache relief within 2 hours after intake. Moreover, Xefocam rapid was the most effective across all groups in achieving complete headache relief within the first 30 minutes. The greatest reduction in the numerical rating scale (NRS) score was also observed in the Xefocam rapid and Xefocam groups. In addition, Xefocam and Xefocam use demonstrated the lowest need for additional medications for pain relief among all groups, which may be related to the rapid onset of analgesic action and high safety profile of these drugs. Patients in the Xefocam rapid group more frequently rated their satisfaction with the therapy as excellent.

Conclusion. Xefocam rapid showed a high safety profile and excellent tolerability, with the lowest incidence of adverse events among all study groups.

1. Deuschl G, Beghi E, Fazekas F, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020 Oct;5(10):e551-e567. doi: 10.1016/S24682667(20)30190-0

2. GBD 2017 US Neurological Disorders Collaborators; Feigin VL, Vos T, Alahdab F, et al. Burden of Neurological Disorders Across the US From 1990–2017: A Global Burden of Disease Study. JAMA Neurol. 2021 Feb 1;78(2):165-76. doi: 10.1001/jamaneurol.2020.4152

3. Ashina S, Mitsikostas DD, Lee MJ, et al. Tension-type headache. Nat Rev Dis Primers.2021 Mar 25;7(1):24. doi: 10.1038/s41572-02100257-2

4. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202

5. Tension-type headache (TTH). Clinical guidelines. All-Russian Society of Neurologists, Russian Society for the Study of Headache. 2021. Available at: https://painrussia.ru/publications/reference-materials-and-guides/%D0%9A%D0%A0%20%D0%93%D0 %91%D0%9D%202021.pdf (accessed 10.12.2024) (In Russ.).

6. Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. Clin Pharmacol Ther. 2021 May;109(5):1212-8. doi: 10.1002/cpt.2083. Epub 2020 Nov 12.

7. Jensen RH. Tension-Type Headache – The Normal and Most Prevalent Headache. Headache. 2018 Feb;58(2):339-45. doi: 10.1111/head.13067. Epub 2017 Mar 13.

8. Bendtsen L, Evers S, Linde M, et al; EFNS. EFNS guideline on the treatment of tensiontype headache – report of an EFNS task force.Eur J Neurol. 2010 Nov;17(11):1318-25. doi: 10.1111/j.1468-1331.2010.03070.x

9. Cumplido-Trasmonte C, Fernandez-Gonzalez P, Alguacil-Diego IM, Molina-Rueda F. Manual therapy in adults with tension-type headache: A systematic review. Neurologia (Engl Ed). 2021 Sep;36(7):537-47. doi: 10.1016/j.nrleng.2017.12.005

10. Lyngberg AC, Rasmussen BK, Jorgensen T,Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur J Epidemiol. 2005;20(3):243-9. doi: 10.1007/s10654-004-6519-2

11. Moore RA, Derry S, Wiffen PJ, et al.Evidence for efficacy of acute treatment of episodic tension-type headache: methodological critique of randomised trials for oral treatments. Pain. 2014 Nov;155(11):2220-8. doi: 10.1016/j.pain.2014.08.009. Epub 2014 Aug 17.

12. Bendtsen L, Bigal ME, Cerbo R, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia. 2010 Jan;30(1):1-16. doi: 10.1111/j.14682982.2009.01948.x

13. WMA Declaration of Helsinki – EthicalPrinciples for Medical Research Involving Human Participants. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/

14. Guidelines for GoodPharmacoepidemiology Practices (GPP). Available at: https://www.pharmacoepi.org/resources/policies/guidelines-08027/ (accessed 10.12.2024).

15. Good Pharmacovigilance Practices.Available at: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices (accessed 10.12.2024).

16. Good Clinical Practice. Available at: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/goodclinical-practice (accessed 10.12.2024).

17. Sergeev AV. Practical use of non-steroid anti-inflammatory drugs in cephalgia treatment: clinical and scientific evidence review. Consilium Medicum. 2018;20(9):39-46. doi: 10.26442/2075-1753_2018.9.39-46 (In Russ.).

18. Kotova OV, Belyaev AA, Akarachkova ES. Tension headache: clinic, diagnosis, treatment. Consilium Medicum. 2020;22(9):68-70. doi: 10.26442/20751753.2020.9.200458 (In Russ.).

19. Schachtel BP, Furey SA, Thoden WR.Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J Clin Pharmacol. 1996 Dec;36(12):1120-5. doi: 10.1002/j.1552-4604.1996.tb04165.x

20. Nebe J, Heier M, Diener HC. Low-doseibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia. 1995 Dec;15(6):531-5. doi: 10.1046/j.1468-2982.1995.1506531.x

21. Mathew N, Ashina M. Acute pharmacotherapy of tension-type headaches. In: Olesen J, Goadsby PJ, Ramadan N, et al, eds. The Headaches. Philadelphia: Lippincott Williams Wilkins; 2005. P. 727-33.

22. Ashina S, Ashina M. Current and potentialfuture drug therapies for tension-type headache. Curr Pain Headache Rep. 2003 Dec;7(6):466-74. doi: 10.1007/s11916-003-0063-8

23. Berg J, Fellier H, Christoph T, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474

24. General characteristics of the medicinal product Xefocam Rapid, LP-No. (008133)-(RG-RU) dated 16.12.2024 (In Russ.).

25. General characteristics of the medicinal product Xefocam, tablets, LP-No. (006807)-(RG-RU), 2024 dated 03.09.2024 (In Russ.).

26. Parada L, Marstein JP, Danilov A.Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016 Oct;6(5):445-54. doi: 10.2217/pmt.16.7. Epub 2016 Apr 18.